



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

12.11.2021

Corporate Services Department,  
BSE Ltd.,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai- 400001

Dear Sir,

**Sub: Outcome Of Board Meeting**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Friday, 12<sup>th</sup> November, 2021, at 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034**, have inter-alia-

1. Approved the Standalone and Consolidated Unaudited Financial Results and Limited Review Report for the quarter ended 30<sup>th</sup> September, 2021.

In terms of the Provisions of Regulation 33 and of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Unaudited Financial Results for the quarter ended 30<sup>th</sup> September, 2021.
2. Limited Review Report for the quarter ended 30<sup>th</sup> September, 2021.

The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 03:40 P.M.

The above information will be available on the website of the Company i.e. <https://titanbiotechltd.com>

This is for your kind information and record please.

Thanking you,  
Yours faithfully,  
For Titan Biotech Limited

  
Charanjit Singh  
Company Secretary  
Membership Number: A12726

**R.O. & Works:** Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan  
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

**E-mail:** [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)

**Website:** [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)




**Sunita Agrawal & Co.**  
(Chartered Accountants)

**Independent Auditor's Limited Review Report**

**To the Board of Directors of TITAN BIOTECH LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **TITAN BIOTECH LIMITED** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the Quarter/ six months ended **30<sup>th</sup> Sept, 2021** ("the Statement") being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to group financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes results of the Holding Company- Titan Biotech Limited and subsidiary Company - Peptech Biosciences Limited.
5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its subsidiary which have been approved and furnished to us by the management. Our conclusion on the Statement is not modified in respect of the above matter.
6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunita Agrawal & Co  
Chartered Accountants  
ICAI FRN-515225C

  
(CA Sunita Agrawal)

Partner  
Membership No.095196  
UDIN-21095196AAAAOU4721



Delhi, November 12, 2021

**Head Office :** 10, Giriraj Nagar, Inside Fort, Bharatpur (Rajasthan)-321001, Ph. : 05644-225679, M : 9899567391  
**Branch Office :** A-160, Boulevard, Hotel Crowne Plaza, Mayur Vihar, Phase-1, Delhi-110091, Ph. : 011-49868379

**E-mail :** sunita\_97@yahoo.com | sac.ical@gmail.com | info@taxfirst.in

**Web :** www.consultants.tax, www.taxfirst.in




**Sunita Agrawal & Co.**  
(Chartered Accountants)

**Independent Auditor's Limited Review Report**

**To the Board of Directors of TITAN BIOTECH LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **TITAN BIOTECH LIMITED** (the "Company") for the quarter/ six months ended **30<sup>th</sup> Sept, 2021** (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Regulation") as amended, read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 (the "Circular").
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunita Agrawal & Co  
Chartered Accountants  
ICAI FRN- 515225C

  
(CA Sunita Agrawal)  
Partner  
Membership No.095196  
UDIN- 21095196AAAAOT8365



Delhi, November 12, 2021

**Head Office :** 10, Giriraj Nagar, Inside Fort, Bharatpur (Rajasthan)-321001, Ph. : 05644-225679, M : 9899567391  
**Branch Office :** A-160, Boulevard, Hotel Crowne Plaza, Mayur Vihar, Phase-1, Delhi-110091, Ph. : 011-49868379

**E-mail :** sunitaca\_97@yahoo.com | sac.icai@gmail.com | info@taxfirst.in

**Web :** www.consultants.tax, www.taxfirst.in



**TITAN BIOTECH LIMITED**  
 Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019  
 Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387  
**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPT. 2021**  
 (Rs. IN LAKHS) except for EPS

| Sr. No | PARTICULARS                                                                   | STANDALONE      |                 |                 |                  |                 |                  |
|--------|-------------------------------------------------------------------------------|-----------------|-----------------|-----------------|------------------|-----------------|------------------|
|        |                                                                               | QUARTER ENDED   |                 |                 | SIX MONTHS ENDED |                 | YEAR ENDED       |
|        |                                                                               | 30.09.2021      | 30.06.2021      | 30.09.2020      | 30.09.2021       | 30.09.2020      | 31.03.2021       |
|        |                                                                               | UNAUDITED       | UNAUDITED       | UNAUDITED       | UNAUDITED        | UNAUDITED       | AUDITED          |
| 1      | <b>INCOME</b>                                                                 |                 |                 |                 |                  |                 |                  |
|        | Revenue from operations                                                       | 2,966.41        | 3,282.18        | 2,716.58        | 6,248.59         | 6,207.51        | 12,245.94        |
|        | Other Income                                                                  | 24.76           | 12.42           | 12.34           | 37.18            | 32.43           | 65.99            |
|        | <b>Total Income</b>                                                           | <b>2,991.17</b> | <b>3,294.60</b> | <b>2,728.92</b> | <b>6,285.77</b>  | <b>6,239.94</b> | <b>12,311.93</b> |
| 2      | <b>EXPENSES</b>                                                               |                 |                 |                 |                  |                 |                  |
|        | Cost of Materials Consumed                                                    | 1,475.15        | 1,491.55        | 1,278.02        | 2,966.70         | 2,590.07        | 5,554.05         |
|        | Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress | 61.16           | 6.81            | (186.65)        | 67.97            | (259.95)        | (222.63)         |
|        | Employee Benefit Expenses                                                     | 348.30          | 313.60          | 281.68          | 661.90           | 531.37          | 1,204.36         |
|        | Finance Costs                                                                 | 19.09           | 23.98           | 37.25           | 43.07            | 62.11           | 127.54           |
|        | Depreciation and Amortization Expenses                                        | 55.44           | 55.04           | 44.80           | 110.48           | 88.59           | 210.41           |
|        | Other Expenses                                                                | 404.58          | 367.32          | 364.87          | 771.90           | 698.37          | 1,529.61         |
|        | <b>Total Expenses</b>                                                         | <b>2,363.72</b> | <b>2,258.30</b> | <b>1,819.97</b> | <b>4,622.02</b>  | <b>3,710.56</b> | <b>8,403.34</b>  |
| 3      | Profit/(loss) before exceptional items and tax (1-2)                          | 627.45          | 1,036.30        | 908.95          | 1,663.75         | 2,529.38        | 3,908.59         |
| 4      | Exceptional Items                                                             | -               | -               | -               | -                | 9.01            | (32.44)          |
| 5      | Profit/ (loss) before tax (3+4)                                               | 627.45          | 1,036.30        | 908.95          | 1,663.75         | 2,538.39        | 3,876.15         |
| 6      | Tax expense:                                                                  |                 |                 |                 |                  |                 |                  |
|        | I) Current Tax                                                                | 124.02          | 290.43          | 223.14          | 414.45           | 627.70          | 984.75           |
|        | II) Deferred Tax                                                              | 2.03            | 1.89            | 5.63            | 3.92             | 11.16           | 13.11            |
|        | (III) Earlier year taxes                                                      | -               | -               | 1.26            | 0.00             | 1.26            | 1.02             |
|        | <b>Total Tax (I+II)</b>                                                       | <b>126.05</b>   | <b>292.32</b>   | <b>230.03</b>   | <b>418.37</b>    | <b>640.12</b>   | <b>998.88</b>    |
| 7      | Profit (Loss) for the period after Tax (5-6)                                  | <b>501.40</b>   | <b>743.98</b>   | <b>678.92</b>   | <b>1,245.38</b>  | <b>1,898.27</b> | <b>2,877.27</b>  |
| 8      | <b>Other comprehensive income (Net of Tax)</b>                                |                 |                 |                 |                  |                 |                  |
| A      | Items that will not be reclassified to profit or loss                         | -               | -               | -               | -                | -               | 6.04             |
|        | Re-measurement gain on defined benefit plans                                  | -               | -               | -               | -                | -               | -                |
| B      | (i) Items that will be reclassified to profit or loss                         | -               | -               | -               | -                | -               | -                |
|        | (ii) Income tax relating to items that will be reclassified to profit or loss | -               | -               | -               | -                | -               | -                |
|        | <b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>    | <b>-</b>        | <b>-</b>        | <b>-</b>        | <b>-</b>         | <b>-</b>        | <b>6.04</b>      |
| 9      | <b>Total Comprehensive Income for the period (7+8)</b>                        | <b>501.40</b>   | <b>743.98</b>   | <b>678.92</b>   | <b>1,245.38</b>  | <b>1,898.27</b> | <b>2,883.31</b>  |
| 10     | Paid-up equity share capital (Face Value of Rs. 10/- each)                    | 826.37          | 826.37          | 826.37          | 826.37           | 826.37          | 826.37           |
| 11     | Other Equity                                                                  | -               | -               | -               | -                | -               | 5,755.64         |
| 12     | Earnings per equity share (face value of Rs. 10/- each) not annualised        |                 |                 |                 |                  |                 |                  |
|        | (1) Basic                                                                     | 6.07            | 9.00            | 8.22            | 15.07            | 22.97           | 34.82            |
|        | (2) Diluted                                                                   | 6.07            | 9.00            | 8.22            | 15.07            | 22.97           | 34.82            |

**Notes:**

- The above unaudited standalone financial results for the quarter and six months ended on 30.09.2021 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on November 12, 2021. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30th Sept. 2021 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The Company continues to closely monitor the impact of COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, based on the information available to date, both internal and external, while preparing the company financial results for the quarter and six months ended on 30th Sept. 2021.
- The total sale for the quarter ended 30.09.2021 includes sale of Products of Rs. 156.43 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- During the year, the company paid Rs. 1.00 Lakhs towards Corporate Social Responsibility (CSR) expenditure.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448

Place : Delhi  
Dated : 12.11.2021



| Sr. No. | PARTICULARS                                                                                                                                           | STANDALONE    |            |            |                  |            |            |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------|------------|------------------|------------|------------|
|         |                                                                                                                                                       | QUARTER ENDED |            |            | SIX MONTHS ENDED |            | YEAR ENDED |
|         |                                                                                                                                                       | 30.09.2021    | 30.06.2021 | 30.09.2020 | 30.09.2021       | 30.09.2020 | 31.03.2021 |
|         |                                                                                                                                                       | UNAUDITED     | UNAUDITED  | UNAUDITED  | UNAUDITED        | UNAUDITED  | AUDITED    |
| 1       | Total Income from Operations (Net)                                                                                                                    | 2,991.17      | 3,294.60   | 2,728.92   | 6,285.77         | 6,239.94   | 12,311.93  |
| 2       | Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)                                                                 | 627.45        | 1,036.30   | 908.95     | 1,663.75         | 2,529.38   | 3,908.59   |
| 3       | Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)                                                            | 627.45        | 1,036.30   | 908.95     | 1,663.75         | 2,538.39   | 3,876.15   |
| 4       | Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)                                                             | 501.40        | 743.98     | 678.92     | 1,245.38         | 1,898.27   | 2,877.27   |
| 5       | Total comprehensive income for the period (comprising Profit/(Loss) for the period(after tax) and Other Comprehensive income(after tax)(refer note 3) | 501.40        | 743.98     | 678.92     | 1,245.38         | 1,898.27   | 2,883.31   |
| 6       | Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)                                                                                      | 826.37        | 826.37     | 826.37     | 826.37           | 826.37     | 826.37     |
| 7       | Other Equity excluding Revaluation Reserves as per the balance sheet                                                                                  | -             | -          | -          | -                | -          | 5,755.64   |
| 8       | Earning Per Share (of INR 10/- each)                                                                                                                  |               |            |            |                  |            |            |
|         | (a) Basic                                                                                                                                             | 6.07          | 9.00       | 8.22       | 15.07            | 22.97      | 34.82      |
|         | (b) Diluted                                                                                                                                           | 6.07          | 9.00       | 8.22       | 15.07            | 22.97      | 34.82      |

**NOTES :**

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter six months ended on 30.09.2021 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter and six months ended on 30.09.2021 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above unaudited standalone financial results for the quarter and six months ended on 30.09.2021 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on November 12, 2021. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30th Sept. 2021 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The Company continues to closely monitor the impact of COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, based on the information available to date, both internal and external, while preparing the company financial results for the quarter and six months ended on 30th Sept.2021.
- The total sale for the quarter ended 30.09.2021 includes sale of Products of Rs. 156.43 Lakhs the demand for which arose due to Covid 19 Pandemic.**
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- During the year, the company paid Rs. 1.00 Lakhs towards Corporate Social Responsibility (CSR) expenditure.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448



Place : Delhi  
Dated : 12.11.2021



**TITAN BIOTECH LIMITED**  
Standalone Balance Sheet as at 30th Sept. 2021

(Rs. in Lakhs.)

| Particulars                               | As at                   |                       |
|-------------------------------------------|-------------------------|-----------------------|
|                                           | 30/09/2021<br>Unaudited | 31/03/2021<br>Audited |
| <b>I ASSETS</b>                           |                         |                       |
| <b>1. Non-Current Assets</b>              |                         |                       |
| a. Property, Plant and Equipment          | 2,463.53                | 2,497.62              |
| b. Capital Work-in-Progress               | 153.45                  | 27.05                 |
| c. Right of use Assets                    | 953.33                  | 196.94                |
| d. Intangible assets                      | 12.17                   | 9.17                  |
| e. Financial Assets                       |                         |                       |
| (i) Investments                           | 127.50                  | 127.50                |
| (ii) Other Financial Assets               | 96.33                   | 745.19                |
| <b>Total Non-current assets</b>           | <b>3,806.31</b>         | <b>3,603.47</b>       |
| <b>2. Current Assets</b>                  |                         |                       |
| a. Inventories                            | 3,235.67                | 2,682.82              |
| b. Financial Assets                       |                         |                       |
| (i) Trade receivables                     | 1,706.73                | 1,611.72              |
| (ii) Cash and cash equivalents            | 342.32                  | 530.86                |
| (iii) Bank balances other than (ii) above | 21.86                   | 18.39                 |
| c. Current Tax Assets (Net)               | -                       | -                     |
| d. Other Current Assets                   | 246.73                  | 169.75                |
| <b>Total Current assets</b>               | <b>5,553.31</b>         | <b>5,013.54</b>       |
| <b>TOTAL ASSETS</b>                       | <b>9,359.62</b>         | <b>8,617.01</b>       |
| <b>II. EQUITY AND LIABILITIES</b>         |                         |                       |
| <b>A Equity</b>                           |                         |                       |
| a. Equity Share Capital                   | 826.37                  | 826.37                |
| b. Other Equity                           | 6,877.06                | 5,755.64              |
| <b>TOTAL EQUITY</b>                       | <b>7,703.43</b>         | <b>6,582.01</b>       |
| <b>B Liabilities</b>                      |                         |                       |
| <b>1. Non-Current Liabilities</b>         |                         |                       |
| a. Financial Liabilities                  |                         |                       |
| (i) Borrowings                            | 268.96                  | 182.68                |
| (ii) Lease liabilities                    | 137.86                  | 139.83                |
| b. Deferred tax liabilities (Net)         | 138.74                  | 134.83                |
| c. Provisions                             | 141.13                  | 141.13                |
| <b>Total Non-Current Liabilities</b>      | <b>686.69</b>           | <b>598.47</b>         |
| <b>2. Current Liabilities</b>             |                         |                       |
| a. Financial Liabilities                  |                         |                       |
| (i) Borrowings                            | 172.73                  | 570.89                |
| (ii) Lease liabilities                    | 14.48                   | 25.02                 |
| (iii) Trade payables                      | 290.31                  | 268.47                |
| (iv) Other financial liabilities          | 301.51                  | 404.82                |
| b. Other current liabilities              | 128.70                  | 159.24                |
| c. Current Tax Liabilities (Net)          | 61.77                   | 8.09                  |
| <b>Total Current Liabilities</b>          | <b>969.50</b>           | <b>1,436.53</b>       |
| <b>TOTAL EQUITY AND LIABILITIES</b>       | <b>9,359.62</b>         | <b>8,617.01</b>       |

For Titan Biotech Limited

[Naresh Kumar Singla]  
Managing Director  
DIN-00027448

Place : Delhi  
Date : 12.11.2021





**TITAN BIOTECH LIMITED**  
**Standalone Cash Flow Statement for the period ended 30th Sept. 2021**

(Rs. in Lakhs.)

| Particulars                                                  | Period ended            | Year ended            |
|--------------------------------------------------------------|-------------------------|-----------------------|
|                                                              | 30/09/2021<br>Unaudited | 31/03/2021<br>Audited |
| <b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>                |                         |                       |
| Profit before Tax                                            | 1,663.75                | 3,876.15              |
| <b>Adjustment for :</b>                                      |                         |                       |
| Finance Costs                                                | 43.07                   | 127.54                |
| Provisions                                                   | -                       | 25.30                 |
| Earlier year Taxes                                           | -                       | (1.02)                |
| Depreciation and Amortization Expenses                       | 110.48                  | 210.41                |
| Operating profit before working capital changes              | 1,817.30                | 4,238.38              |
| Changes in working Capital:                                  |                         |                       |
| Inventories                                                  | (552.85)                | (268.79)              |
| Trade and other Receivables                                  | 476.86                  | (1,244.78)            |
| Trade and other Payables                                     | (112.00)                | 65.34                 |
| Cash generation from Operation                               | 1,629.31                | 2,790.13              |
| Payment of Direct Taxes                                      | (360.78)                | (1,015.62)            |
| <b>Net Cash generated/ (used) - Operating Activities</b>     | 1,268.53                | 1,774.51              |
| <b>B. CASH FLOW FROM INVESTMENT ACTIVITIES</b>               |                         |                       |
| Purchase of Fixed Assets (incl.Capital WIP)                  | (205.78)                | (271.26)              |
| Right of use assets                                          | (756.39)                | (146.03)              |
| Movement in Fixed Deposits with Banks                        | (3.47)                  | (15.93)               |
| <b>Net Cash Generated/ (Used) - Investing Activities</b>     | (965.64)                | (433.22)              |
| <b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>                |                         |                       |
| Repayment of Long-term Borrowings                            | 86.27                   | (665.13)              |
| Repayment of Lease Liabilities                               | (12.51)                 | 164.85                |
| Proceeds/(Repayment) of Short-term Borrowings (Net)          | (398.16)                | (270.07)              |
| Finance Cost paid                                            | (43.07)                 | (127.54)              |
| Dividend paid                                                | (123.96)                | (82.64)               |
| <b>Net Cash Generated/ (Used) - Financing Activities</b>     | (491.43)                | (980.53)              |
| <b>Net Increase/ (Decrease) in Cash and Cash Equivalents</b> | (188.54)                | 360.76                |
| Add : Opening Cash and Cash Equivalents                      | 530.86                  | 170.10                |
| <b>Closing Cash and Cash Equivalents (refer note-8)</b>      | 342.32                  | 530.86                |

**Notes:**

1. The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
2. Figures in bracket represent outflows.
3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

Place : Delhi  
Date : 12.11.2021

For Titan Biotech Limited

(Naresh Kumar Singh)  
Managing Director  
DIN-00027448



## TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPT. 2021  
(Rs. IN LAKHS) except for EPS

| Sr. No | PARTICULARS                                                                   | CONSOLIDATED    |                 |                 |                  |                 |                  |
|--------|-------------------------------------------------------------------------------|-----------------|-----------------|-----------------|------------------|-----------------|------------------|
|        |                                                                               | QUARTER ENDED   |                 |                 | SIX MONTHS ENDED |                 | YEAR ENDED       |
|        |                                                                               | 30.09.2021      | 30.06.2021      | 30.09.2020      | 30.09.2021       | 30.09.2020      | 31.03.2021       |
|        |                                                                               | UNAUDITED       | UNAUDITED       | UNAUDITED       | UNAUDITED        | UNAUDITED       | AUDITED          |
| 1      | <b>INCOME</b>                                                                 |                 |                 |                 |                  |                 |                  |
|        | Revenue from operations                                                       | 4,085.52        | 4,143.97        | 3,265.63        | 8,229.49         | 7,207.49        | 14,223.72        |
|        | Other Income                                                                  | 25.66           | 14.35           | 16.55           | 40.01            | 39.91           | 78.84            |
|        | <b>Total Income</b>                                                           | <b>4,111.18</b> | <b>4,158.32</b> | <b>3,282.18</b> | <b>8,269.50</b>  | <b>7,247.40</b> | <b>14,302.56</b> |
| 2      | <b>EXPENSES</b>                                                               |                 |                 |                 |                  |                 |                  |
|        | Cost of Materials Consumed                                                    | 2,143.25        | 1,955.90        | 1,606.84        | 4,099.15         | 3,143.00        | 6,730.24         |
|        | Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress | 45.68           | (23.87)         | (187.56)        | 21.81            | (254.89)        | (273.41)         |
|        | Employee Benefit Expenses                                                     | 399.07          | 365.20          | 329.87          | 764.27           | 624.06          | 1,405.23         |
|        | Finance Costs                                                                 | 36.37           | 37.53           | 46.57           | 73.90            | 83.68           | 166.76           |
|        | Depreciation and Amortization Expenses                                        | 62.45           | 58.40           | 46.33           | 120.85           | 91.58           | 221.73           |
|        | Other Expenses                                                                | 449.88          | 406.00          | 425.97          | 855.88           | 787.41          | 1,749.01         |
|        | <b>Total Expenses</b>                                                         | <b>3,136.70</b> | <b>2,799.16</b> | <b>2,268.02</b> | <b>5,935.86</b>  | <b>4,474.84</b> | <b>9,999.56</b>  |
| 3      | Profit/(loss) before exceptional items and tax (1-2)                          | 974.48          | 1,359.16        | 1,014.16        | 2,333.64         | 2,772.56        | 4,303.00         |
| 4      | Exceptional Items                                                             | -               | -               | -               | -                | 9.00            | (32.44)          |
| 5      | Profit/ (loss) before tax (3+4)                                               | 974.48          | 1,359.16        | 1,014.16        | 2,333.64         | 2,781.56        | 4,270.56         |
| 6      | Tax expense:                                                                  |                 |                 |                 |                  |                 |                  |
|        | I) Current Tax                                                                | 212.03          | 371.77          | 248.72          | 583.80           | 688.23          | 1,085.57         |
|        | II) Earlier year taxes                                                        | 0.24            | -               | 1.26            | 0.24             | 1.26            | 0.56             |
|        | III) Deferred Tax                                                             | 1.34            | 1.81            | 6.07            | 3.15             | 11.83           | 13.90            |
|        | <b>Total Tax (I+II)</b>                                                       | <b>213.61</b>   | <b>373.58</b>   | <b>256.05</b>   | <b>587.19</b>    | <b>701.32</b>   | <b>1,100.03</b>  |
| 7      | Profit (Loss) for the period after Tax (5-6)                                  | 760.87          | 985.58          | 758.11          | 1,746.45         | 2,080.24        | 3,170.53         |
| 8      | <b>Other comprehensive income (Net of Tax)</b>                                |                 |                 |                 |                  |                 |                  |
| A.     | Items that will not be reclassified to profit or loss                         | -               | -               | -               | -                | -               | 5.21             |
|        | Re-measurement gain on defined benefit plans                                  | -               | -               | -               | -                | -               | -                |
| (i)    | Items that will be reclassified to profit or loss                             | -               | -               | -               | -                | -               | -                |
| B      | (ii) Income tax relating to items that will be reclassified to profit or loss | -               | -               | -               | -                | -               | -                |
|        | <b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>    | <b>-</b>        | <b>-</b>        | <b>-</b>        | <b>-</b>         | <b>-</b>        | <b>5.21</b>      |
| 9      | <b>Total Comprehensive Income for the period (7+8)</b>                        | <b>760.87</b>   | <b>985.58</b>   | <b>758.11</b>   | <b>1,746.45</b>  | <b>2,080.24</b> | <b>3,175.74</b>  |
| 10     | <b>Net profit attributable to:</b>                                            |                 |                 |                 |                  |                 |                  |
|        | Owners of the holding company                                                 | 639.23          | 872.32          | 720.99          | 1,511.55         | 1,994.93        | 3,033.52         |
|        | Non-controlling interest                                                      | 121.64          | 113.26          | 37.12           | 234.90           | 85.31           | 137.01           |
| 11     | <b>Other comprehensive income attributable to:</b>                            |                 |                 |                 |                  |                 |                  |
|        | Owners of the holding company                                                 | -               | -               | -               | -                | -               | 5.60             |
|        | Non-controlling interest                                                      | -               | -               | -               | -                | -               | (0.39)           |
| 12     | <b>Total Comprehensive Income attributable to (10+11)</b>                     |                 |                 |                 |                  |                 |                  |
|        | Owners of the holding company                                                 | 639.23          | 872.32          | 720.99          | 1,511.55         | 1,994.93        | 3,039.12         |
|        | Non-controlling interest                                                      | 121.64          | 113.26          | 37.12           | 234.90           | 85.31           | 136.62           |
| 13     | Paid-up equity share capital (Face Value of Rs. 10/- each)                    | 826.37          | 826.37          | 826.37          | 826.37           | 826.37          | 826.37           |
| 14     | Other Equity                                                                  | -               | -               | -               | -                | -               | 6,049.45         |
| 15     | Earnings per equity share (face value of Rs. 10/- each) not annualised        |                 |                 |                 |                  |                 |                  |
| (1)    | Basic                                                                         | 7.74            | 10.56           | 8.72            | 18.29            | 24.14           | 36.71            |
| (2)    | Diluted                                                                       | 7.74            | 10.56           | 8.72            | 18.29            | 24.14           | 36.71            |

## Notes:

- The above consolidated unaudited financial results for the quarter and six months ended on 30.09.2021 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on November 12, 2021. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The consolidated unaudited financial results for the quarter and six months ended on 30.09.2021 include the results of following:-  
Subsidiary Company - Peptech Biosciences Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30th Sept. 2021 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The Group continues to closely monitor the impact of COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, based on the information available to date, both internal and external, while preparing the Group's financial results for the quarter and six months ended on 30th Sept. 2021.
- The total sale for the quarter ended 30.09.2021 includes sale of Products of Rs. 156.43 Lakhs the demand for which arose due to Covid 19 Pandemic.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- During the year, the company paid Rs. 1.00 Lakhs towards Corporate Social Responsibility (CSR) expenditure.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITEDNARESH KUMAR SINGLA  
Managing Director  
DIN-00027448Place : Delhi  
Dated : 12.11.2021



**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPT. 2021**

(Rs. IN LAKHS) except for EPS

| S.NO. | PARTICULARS                                                                                                                                           | CONSOLIDATED  |            |            |                  |            |            |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------|------------|------------------|------------|------------|
|       |                                                                                                                                                       | QUARTER ENDED |            |            | SIX MONTHS ENDED |            | YEAR ENDED |
|       |                                                                                                                                                       | 30.09.2021    | 30.06.2021 | 30.09.2020 | 30.09.2021       | 30.09.2020 | 31.03.2021 |
|       |                                                                                                                                                       | UNAUDITED     | UNAUDITED  | UNAUDITED  | UNAUDITED        | UNAUDITED  | AUDITED    |
| 1     | Total Income from Operations (Net)                                                                                                                    | 4,111.18      | 4,158.32   | 3,282.18   | 8,269.50         | 7,247.40   | 14,302.56  |
| 2     | Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)                                                                 | 974.48        | 1,359.16   | 1,014.16   | 2,333.64         | 2,772.56   | 4,303.00   |
| 3     | Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)                                                            | 974.48        | 1,359.16   | 1,014.16   | 2,333.64         | 2,781.56   | 4,270.56   |
| 4     | Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)                                                             | 760.87        | 985.58     | 758.11     | 1,746.45         | 2,080.24   | 3,170.53   |
| 5     | Total comprehensive income for the period (comprising Profit/(Loss) for the period(after tax) and Other Comprehensive income(after tax)(refer note 3) | 760.87        | 985.58     | 758.11     | 1,746.45         | 2,080.24   | 3,175.74   |
| 6     | Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)                                                                                      | 826.37        | 826.37     | 826.37     | 826.37           | 826.37     | 826.37     |
| 7     | Other Equity excluding Revaluation Reserves as per the balance sheet                                                                                  |               |            |            |                  | -          | 6,049.45   |
| 8     | Earning Per Share (of INR 10/- each)                                                                                                                  |               |            |            |                  |            |            |
|       | (a) Basic                                                                                                                                             | 7.74          | 10.56      | 8.72       | 18.29            | 24.14      | 36.71      |
|       | (b) Diluted                                                                                                                                           | 7.74          | 10.56      | 8.72       | 18.29            | 24.14      | 36.71      |

**NOTES :**

- The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter and six months ended on 30.09.2021 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter and six months ended on 30th Sept. 2021 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated unaudited financial results for the quarter and six months ended on 30.09.2021 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on November 10, 2021. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30th Sept. 2021 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The Group continues to closely monitor the impact of COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care , in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, based on the information available to date, both internal and external, while preparing the Group's financial results for the quarter and six months ended on 30th Sept. 2021.
- The total sale for the quarter ended 30.09.2021 includes sale of Products of Rs. 156.43 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ( ' Ind AS ' ) specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- During the year, the company paid Rs. 1.00 Lakhs towards Corporate Social Responsibility (CSR) expenditure.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448\*

Place : Delhi  
Dated : 12.11.2021



**TITAN BIOTECH LIMITED**  
**Consolidated Balance Sheet as at 30th Sept. 2021**

(Rs. in Lakhs.)

| Particulars                               | As at                   |                       |
|-------------------------------------------|-------------------------|-----------------------|
|                                           | 30/09/2021<br>Unaudited | 31/03/2021<br>Audited |
| <b>I ASSETS</b>                           |                         |                       |
| <b>1. Non-Current Assets</b>              |                         |                       |
| a. Property, Plant and Equipment          | 2,599.55                | 2,620.91              |
| b. Capital Work-in-Progress               | 206.34                  | 27.05                 |
| c. Right of use Assets                    | 1,532.07                | 730.59                |
| d. Intangible assets                      | 12.17                   | 9.17                  |
| e. Financial Assets                       |                         |                       |
| (i) Other Financial Assets                | 102.08                  | 750.95                |
| f. Other Non Current Assets               | -                       | -                     |
| <b>Total Non-current assets</b>           | <b>4,452.21</b>         | <b>4,138.67</b>       |
| <b>2. Current Assets</b>                  |                         |                       |
| a. Inventories                            | 3,803.82                | 3,253.77              |
| b. Financial Assets                       | -                       | -                     |
| (i) Trade receivables                     | 2,361.93                | 1,810.38              |
| (ii) Cash and cash equivalents            | 400.82                  | 545.06                |
| (iii) Bank balances other than (ii) above | 21.86                   | 18.39                 |
| c. Current Tax Assets (Net)               | -                       | -                     |
| d. Other Current Assets                   | 510.13                  | 305.29                |
| <b>Total Current assets</b>               | <b>7,098.56</b>         | <b>5,932.89</b>       |
| <b>TOTAL ASSETS</b>                       | <b>11,550.77</b>        | <b>10,071.56</b>      |
| <b>II. EQUITY AND LIABILITIES</b>         |                         |                       |
| <b>A Equity</b>                           |                         |                       |
| a. Equity Share Capital                   | 826.37                  | 826.37                |
| b. Other Equity                           | 7,437.04                | 6,049.44              |
| c. Non Controlling Interest               | 606.69                  | 371.79                |
| <b>TOTAL EQUITY</b>                       | <b>8,870.10</b>         | <b>7,247.60</b>       |
| <b>B Liabilities</b>                      |                         |                       |
| <b>1. Non-Current Liabilities</b>         |                         |                       |
| a. Financial Liabilities                  |                         |                       |
| (i) Borrowings                            | 678.99                  | 485.53                |
| (ii) Lease liabilities                    | 184.84                  | 139.83                |
| b. Deferred tax liabilities (Net)         | 142.07                  | 138.92                |
| c. Provisions                             | 148.72                  | 148.72                |
| <b>Total Non-Current Liabilities</b>      | <b>1,154.62</b>         | <b>913.00</b>         |
| <b>2. Current Liabilities</b>             |                         |                       |
| a. Financial Liabilities                  |                         |                       |
| (i) Borrowings                            | 427.02                  | 828.53                |
| (ii) Lease liabilities                    | 16.69                   | 25.02                 |
| (iii) Trade payables                      | 367.88                  | 371.35                |
| (iv) Other Financial Liabilities          | 355.04                  | 471.03                |
| b. Other current liabilities              | 183.54                  | 179.33                |
| c. Current Tax Liabilities (Net)          | 175.88                  | 35.70                 |
| <b>Total Current Liabilities</b>          | <b>1,526.05</b>         | <b>1,910.96</b>       |
| <b>TOTAL EQUITY AND LIABILITIES</b>       | <b>11,550.77</b>        | <b>10,071.56</b>      |

For Titan Biotech Limited

[Naresh Kumar Singla]  
Managing Director  
DIN-00027448

Place : Delhi  
Date : 12.11.2021



**TITAN BIOTECH LIMITED**  
**Consolidated Cash Flow Statement for the period ended 30th Sept. 2021**

| Particulars                                                          | (Rs. in Lakhs.)         |                       |
|----------------------------------------------------------------------|-------------------------|-----------------------|
|                                                                      | Period ended            | Year ended            |
|                                                                      | 30/09/2021<br>Unaudited | 31/03/2021<br>Audited |
| <b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>                        |                         |                       |
| Profit before Tax                                                    | 2,333.65                | 4,270.56              |
| Adjustment for :                                                     | -                       | -                     |
| Finance Costs                                                        | 73.90                   | 166.76                |
| MAT Credit                                                           | -                       | -                     |
| Earlier year Taxes                                                   | (0.24)                  | (0.56)                |
| Provision for employees Benefits                                     | -                       | 27.85                 |
| Depreciation and Amortization Expenses                               | 120.85                  | 221.73                |
| Unamortized Expenses                                                 | -                       | 0.30                  |
| Operating profit before working capital changes                      | 2,528.16                | 4,686.64              |
| Changes in working Capital:                                          |                         |                       |
| Inventories                                                          | (550.05)                | (456.20)              |
| Trade and other Receivables                                          | (107.51)                | (1,369.22)            |
| Trade and other Payables                                             | (115.25)                | 151.29                |
| Cash generation from Operation                                       | 1,755.35                | 3,012.51              |
| Payment of Direct Taxes                                              | (443.64)                | (1,088.37)            |
| <b>Net Cash generated/ (used) - Operating Activities</b>             | <b>1,311.71</b>         | <b>1,924.14</b>       |
| <b>B. CASH FLOW FROM INVESTMENT ACTIVITIES</b>                       |                         |                       |
| Purchase of Fixed Assets (incl. Capital WIP and Right of use assets) | (281.79)                | (301.08)              |
| Right of use assets                                                  | (801.48)                | (185.41)              |
| Proceeds/ Repayment of Loans to Body Corporate (Net)                 | -                       | -                     |
| Movement in Fixed Deposits with Banks                                | (3.47)                  | (15.93)               |
| <b>Net Cash Generated/ (Used) - Investing Activities</b>             | <b>(1,086.74)</b>       | <b>(502.42)</b>       |
| <b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>                        |                         |                       |
| Repayment of Long-term Borrowings                                    | (208.04)                | (975.38)              |
| Repayment of Lease Liabilities                                       | 36.69                   | 164.85                |
| Finance Cost paid                                                    | (73.90)                 | (166.76)              |
| Dividend paid                                                        | (123.96)                | (82.64)               |
| <b>Net Cash Generated/ (Used) - Financing Activities</b>             | <b>(369.21)</b>         | <b>(1,059.93)</b>     |
| <b>Net Increase/ (Decrease) in Cash and Cash Equivalents</b>         | <b>(144.24)</b>         | <b>361.79</b>         |
| Add : Opening Cash and Cash Equivalents                              | 545.06                  | 183.27                |
| <b>Closing Cash and Cash Equivalents</b>                             | <b>400.82</b>           | <b>545.06</b>         |

**Notes:**

1. The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
2. Figures in bracket represent outflows.
3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

Place : Delhi  
Date : 12.11.2021

For Titan Biotech Limited

[Naresh Kumar Singla]  
Managing Director  
DIN-00027448